Further, therapeutic inhibition of COX2 is associated with adverse cardiac events [64] and delayed inflammation resolution [61], suggesting beta-blocker treatment, by increasing PTGS2 expression may be both beneficial in the treatment of preeclampsia and also the long-term increased cardiovascular risks the disease imposes. The gene discussed is PTGS2; the disease is preeclampsia.